Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.75 |
| ▸ | EGFR | P00533 | 8/20 | 0.75 |
| ▸ | LCK | P06239 | 7/20 | 0.75 |
| ▸ | ITK | Q08881 | 7/20 | 0.75 |
| ▸ | JAK3 | P52333 | 2/20 | 0.75 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.55 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410068 | 0.90 | BTK (0.82) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL409226 | 0.89 | BTK (0.76) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL16231133 | 0.89 | BTK (0.76) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14617765 | 0.86 | BTK (0.76) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL409213 | 0.86 | BTK (0.79) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL408564 | 0.86 | BTK (1.00) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14617791 | 0.84 | BTK (0.78) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL15517319 | 0.84 | BTK (0.81) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL17090646 | 0.84 | BTK (0.80) | BTKEGFRLCKITKJAK3 | |
| SCHEMBL14643776 | 0.83 | BTK (0.76) | BTKEGFRLCKITKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230293532-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293532-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20220213106-A1 | Inhibitors of Bruton's Tyrosine Kinase | PHARMACYCLICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2008121742-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| WO-2008039218-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213106-A1 | Inhibitors of Bruton's Tyrosine Kinase | ABL1, BTK, ABL2 | BTK 2/4885EGFR 697/4885LCK 23/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | BTK 1/4885EGFR 1443/4885LCK 67/4885 |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885EGFR 985/4885LCK 5/4885 |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | BTK, LYN, SYK | BTK 1/4885EGFR 985/4885LCK 5/4885 |
| US-20230100137-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | BTK 2/4885EGFR 1605/4885LCK 278/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | BTK 1/4885EGFR 703/4885LCK 2/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | BTK 1/4885EGFR 1536/4885LCK 2/4885 |
| US-20230293532-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885EGFR 985/4885LCK 5/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | BTK 1/4885EGFR 1550/4885LCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.